The ELAVL2 Knockout MES-OV Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for the targeted disruption of the ELAVL2 gene in the human ovarian adenocarcinoma MES-OV cell line. This product provides a heterogeneous pool of cells with diverse CRISPR-mediated mutations, enabling the study of ELAVL2 loss-of-function without clonal selection. The polyclonal nature mimics the genetic variability often observed in tumor populations, making it suitable for investigating gene function in a context that reflects cellular heterogeneity. The knockout population was generated using ribonucleoprotein-based CRISPR/Cas9 delivery and validated at the population level, ensuring robust reduction of target protein expression across the polyclonal pool.
The host cell line, MES-OV, is an epithelial ovarian carcinoma line derived from a human ovarian adenocarcinoma and serves as a well-established model for ovarian cancer research. These cells exhibit adherent epithelial morphology and retain molecular features relevant to high-grade serous ovarian carcinoma, including dysregulated proliferation and invasive potential. The MES-OV background provides a clinically relevant platform for probing the molecular determinants of ovarian tumorigenesis, drug response, and metastasis. By introducing an ELAVL2 knockout in this context, researchers can dissect how post-transcriptional regulatory mechanisms contribute to ovarian cancer pathology.
ELAVL2 encodes an RNA-binding protein that specifically recognizes AU?rich elements (AREs) in the 3?? untranslated regions of target mRNAs, protecting them from deadenylation and subsequent degradation. This stabilization function enhances translation of key neuronal and proliferative transcripts, including FOS, GAP43, NRN1, NEFL, and BDNF. ELAVL2 activity is regulated by upstream transcriptional programs involving NeuroD1, Neurogenin2, and REST, and it interacts with the related RNA-binding proteins ELAVL3, ELAVL4, and the poly(A)-binding protein PABPC1. Mechanistically, ELAVL2 opposes the CCR4?NOT deadenylase complex and exosome-mediated decay, thereby maintaining mRNA stability within cytoplasmic processing bodies and influencing the post-transcriptional landscape.
In MES-OV ovarian cancer cells, ELAVL2 knockout disrupts the normal stabilization of ARE-containing transcripts, leading to altered expression of genes involved in neuronal differentiation and proliferation. This perturbation can modulate tumor cell growth, survival, and migration, highlighting the paradoxical role of neuronal RNA-binding proteins in non-neuronal malignancies. The knockout model enables investigation of how ELAVL2-mediated post-transcriptional control intersects with ovarian cancer signaling networks, potentially revealing novel therapeutic vulnerabilities. Because ELAVL2 targets include immediate-early genes and cytoskeletal regulators, its loss may affect invasive behavior and cellular plasticity in the ovarian tumor microenvironment.
This polyclonal knockout pool is ideally suited for a wide array of functional assays, including RT?qPCR and western blotting for expression analysis, RNA immunoprecipitation to assess protein?RNA interactions, and RNA?seq to globally characterize transcriptomic changes. Cell-based phenotypic studies such as MTT viability assays, colony formation, and migration assays can further delineate the impact on tumorigenic properties. The model supports drug target validation and mechanistic studies of post-transcriptional regulation in ovarian cancer. For further information, please contact Ascent Research.
